Spatial and transcriptomic analyses reveal the adverse prognostic impact of regulatory T cells in follicular lymphoma treated with rituximab–lenalidomide
Abstract
Summary The prognostic impact of the tumour microenvironment in follicular lymphoma (FL) remains controversial. To adress this, we analysed FL samples from patients enrolled in the rituximab lenalidomide versus any chemotherapy (RELEVANCE) trial using RNA‐sequencing (RNA‐seq) and multiplex immunofluorescence (mIF). RNA‐seq analysis ( n = 354) showed that regulatory T‐cell (Treg) signatures were associated with shorter PFS in the whole cohort (HR = 1.56, 95% CI: 1.01–2.41, p = 0.044), particularly in patients treated with rituximab–lenalidomide (LEN) (R2, HR= 1.84, 95% CI: 1–3.37, p = 0.046) but not with rituximab‐chemotherapy (R‐chemo, HR = 1.33, 95% CI: 0.71–2.48, p = 0.365). mIF analysis on tissue microarrays (TMA) ( n = 394) showed that high infiltration of CD3 + /CD4 + /FOXP3 + Tregs was associated with shorter PFS in the overall cohort (HR = 1.951, CI: 1.259–3.024, p = 0.0023 log‐rank test), particularly in the R2 arm (HR = 2.3, CI: 1.2–4.5, p = 0.0097 log‐rank test) and remained significant after FL‐International Prognostic Index (FLIPI) adjustment (HR = 1.843; 95% CI: 1.1–2.8, p = 0.006). Whole‐slide mIF (WSI) performed in 64 selected cases confirmed the adverse prognostic impact of Tregs in R2‐treated patients and further showed that extra‐follicular Treg localization was specifically associated with shorter PFS (HR = 2.87, 95% CI: 1.13–7.28, p = 0.020). These data suggest that high Treg infiltration by mIF is associated with inferior outcome in lenalidomide‐treated FL patients and may have potential value for risk stratification.